GW Pharmaceuticals Plc is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It offers its cannabinoid product, Epidiolex oral solution CV, a pharmaceutical formulation of cannabidiol (CBD) focusing on the treatment of seizures associated with tuberous sclerosis complex. The company was founded by Geoffrey William Guy and Brian Whittle in 1998 and is headquartered in Cambridge, the United Kingdom.
Company profile
Ticker
GWPRF, GWPRF
Exchange
Website
CEO
Justin Gover
Employees
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
GW Pharma Limited • GW Research Limited • Greenwich Biosciences, Inc. • GWP Trustee Company Limited • GW Pharmaceuticals Australia • GW UK Services Limited • GW Global Services (International) Limited • G-Pharm Limited • GW Pharma (Germany) GmbH • GW Pharma (Italy) S.R.L. ...
GWPRF stock data
Latest filings (excl ownership)
15-12B
Securities registration termination
17 May 21
S-8 POS
Registration of securities for employees (post-effective amendment)
5 May 21
S-8 POS
Registration of securities for employees (post-effective amendment)
5 May 21
S-8 POS
Registration of securities for employees (post-effective amendment)
5 May 21
POSASR
Automatic shelf registration (post-effective amendment)
5 May 21
8-K
Jazz Pharmaceuticals Completes Acquisition of GW Pharmaceuticals plc
5 May 21
25-NSE
Exchange delisting
5 May 21
10-Q
2021 Q1
Quarterly report
3 May 21
10-K/A
2020 FY
Annual report (amended)
30 Apr 21
8-K
GW Pharmaceuticals Shareholders Approve Acquisition by Jazz Pharmaceuticals
23 Apr 21
Transcripts
GWPRF
Earnings call transcript
2020 Q3
3 Nov 20
GWPRF
Earnings call transcript
2020 Q3
3 Nov 20
GWPRF
Earnings call transcript
2020 Q2
6 Aug 20
GWPRF
Earnings call transcript
2020 Q1
11 May 20
GWPRF
Earnings call transcript
2019 Q4
25 Feb 20
GWPRF
Earnings call transcript
2019 Q3
5 Nov 19
GWPRF
Earnings call transcript
2019 Q2
6 Aug 19
GWPRF
Earnings call transcript
2019 Q1
6 May 19
GWPRF
Earnings call transcript
2019 Q1
27 Feb 19
GWPRF
Earnings call transcript
2018 Q4
27 Nov 18
Latest ownership filings
Financial summary
Quarter (USD) | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 20 | Dec 19 | Sep 18 | Sep 17 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 458.10 mm | 458.10 mm | 458.10 mm | 458.10 mm | 458.10 mm | 458.10 mm |
Cash burn (monthly) | 9.55 mm | 3.57 mm | 7.25 mm | 5.99 mm | 3.91 mm | 1.71 mm |
Cash used (since last report) | 350.02 mm | 130.82 mm | 265.59 mm | 219.58 mm | 143.20 mm | 62.64 mm |
Cash remaining | 108.09 mm | 327.28 mm | 192.51 mm | 238.52 mm | 314.90 mm | 395.46 mm |
Runway (months of cash) | 11.3 | 91.7 | 26.6 | 39.8 | 80.6 | 231.4 |
Institutional ownership, Q1 2022
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|